Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830219 · ClinicalTrials.gov registry record · Phase 1
The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00830219: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00830219 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00830219, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to compare relative bioavailability of the test formulation of ropinirole hydrochloride 0.25 mg tablets (Manufactured and distributed by TEVA Pharmaceuticals USA) with the already approved formulation REQUIP® (ropinirole hydrochloride) 0.25 mg tablets (GlaxoSmithKline) under fed conditions in healthy, adult subjects.
Primary Outcome
Bioequivalence based on Cmax.
Interventions
- DRUG Ropinirole HCl 0.25 mg Tablets
- DRUG Requip® 0.25 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2004-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
What the finished NCT00830219 record still lists
NCT00830219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Ropinirole HCl 0.25 mg Tablets is the first listed.
NCT00830219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00830219 about?
NCT00830219 is a clinical study titled "The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions". The purpose of this study is to compare relative bioavailability of the test formulation of ropinirole hydrochloride 0.25 mg tablets (Manufactured and distributed by TEVA Pharmaceuticals USA) with the already approved formulation REQUIP® (ropinirole hydrochloride) 0.25 mg tablets (GlaxoSmithKline) u...
What is the current status of trial NCT00830219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2004-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00830219?
The interventions under investigation include: Ropinirole HCl 0.25 mg Tablets (DRUG), Requip® 0.25 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00830219?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00830219's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia